Company intelligence / Profile preview
Beijing Institute of Biological Products
- Ownership
- Private
- Development stage
- Commercial
Overview
Beijing Institute of Biological Products has several vaccines approved and in commercial use, including the inactivated COVID‑19 vaccine (Vero Cell), oral polio vaccines, and MMR vaccines. Their COVID‑19 vaccine received emergency use listing from the WHO and has been widely distributed internationally[6][8][9][10].
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineInactivated vaccineLive attenuated vaccineCombination vaccineAntibody
- Industry
- Pharma
Drug pipeline
16 assets15 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Beijing Institute of Biological Products.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Institute of Biological Products.